These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19591938)

  • 1. A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease.
    Dhaenens CM; Burnouf S; Simonin C; Van Brussel E; Duhamel A; Defebvre L; Duru C; Vuillaume I; Cazeneuve C; Charles P; Maison P; Debruxelles S; Verny C; Gervais H; Azulay JP; Tranchant C; Bachoud-Levi AC; Dürr A; Buée L; Krystkowiak P; Sablonnière B; Blum D;
    Neurobiol Dis; 2009 Sep; 35(3):474-6. PubMed ID: 19591938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age at onset in Huntington's disease: replication study on the association of HAP1.
    Karadima G; Dimovasili C; Koutsis G; Vassilopoulos D; Panas M
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1027-8. PubMed ID: 22698993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.
    Wexler NS; Lorimer J; Porter J; Gomez F; Moskowitz C; Shackell E; Marder K; Penchaszadeh G; Roberts SA; Gayán J; Brocklebank D; Cherny SS; Cardon LR; Gray J; Dlouhy SR; Wiktorski S; Hodes ME; Conneally PM; Penney JB; Gusella J; Cha JH; Irizarry M; Rosas D; Hersch S; Hollingsworth Z; MacDonald M; Young AB; Andresen JM; Housman DE; De Young MM; Bonilla E; Stillings T; Negrette A; Snodgrass SR; Martinez-Jaurrieta MD; Ramos-Arroyo MA; Bickham J; Ramos JS; Marshall F; Shoulson I; Rey GJ; Feigin A; Arnheim N; Acevedo-Cruz A; Acosta L; Alvir J; Fischbeck K; Thompson LM; Young A; Dure L; O'Brien CJ; Paulsen J; Brickman A; Krch D; Peery S; Hogarth P; Higgins DS; Landwehrmeyer B;
    Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3498-503. PubMed ID: 14993615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.
    Andrew SE; Goldberg YP; Kremer B; Telenius H; Theilmann J; Adam S; Starr E; Squitieri F; Lin B; Kalchman MA
    Nat Genet; 1993 Aug; 4(4):398-403. PubMed ID: 8401589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes.
    Chattopadhyay B; Baksi K; Mukhopadhyay S; Bhattacharyya NP
    Neurosci Lett; 2005 Feb; 374(2):81-6. PubMed ID: 15644269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease.
    Kishikawa S; Li JL; Gillis T; Hakky MM; Warby S; Hayden M; MacDonald ME; Myers RH; Gusella JF
    Neurobiol Dis; 2006 Nov; 24(2):280-5. PubMed ID: 16962786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between caffeine intake and age at onset in Huntington's disease.
    Simonin C; Duru C; Salleron J; Hincker P; Charles P; Delval A; Youssov K; Burnouf S; Azulay JP; Verny C; Scherer C; Tranchant C; Goizet C; Debruxelles S; Defebvre L; Sablonnière B; Romon-Rousseaux M; Buée L; Destée A; Godefroy O; Dürr A; Landwehrmeyer B; ; Bachoud-Levi AC; Richard F; Blum D; Krystkowiak P;
    Neurobiol Dis; 2013 Oct; 58():179-82. PubMed ID: 23732677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The gene responsible for Huntington's disease in Spanish families: its diagnostic value and the relation between trinucleotide expansion and the clinical characteristics].
    Benítez J; Fernández E; García Ruiz P; Robledo M; Ayuso C; García Yébenes J
    Rev Clin Esp; 1994 Aug; 194(8):591-3. PubMed ID: 7938836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.
    Langbehn DR; Brinkman RR; Falush D; Paulsen JS; Hayden MR;
    Clin Genet; 2004 Apr; 65(4):267-77. PubMed ID: 15025718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Huntington's Disease-like 2 (HDL2) in North America and Japan.
    Margolis RL; Holmes SE; Rosenblatt A; Gourley L; O'Hearn E; Ross CA; Seltzer WK; Walker RH; Ashizawa T; Rasmussen A; Hayden M; Almqvist EW; Harris J; Fahn S; MacDonald ME; Mysore J; Shimohata T; Tsuji S; Potter N; Nakaso K; Adachi Y; Nakashima K; Bird T; Krause A; Greenstein P
    Ann Neurol; 2004 Nov; 56(5):670-4. PubMed ID: 15468075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-up tilt induced syncope and adenosine A2A receptor gene polymorphism.
    Saadjian AY; Gerolami V; Giorgi R; Mercier L; Berge-Lefranc JL; Paganelli F; Ibrahim Z; By Y; Guéant JL; Lévy S; Guieu RP
    Eur Heart J; 2009 Jun; 30(12):1510-5. PubMed ID: 19386617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between CAG repeat length and clinical progression in Huntington's disease.
    Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
    Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited CAG.CTG allele length is a major modifier of somatic mutation length variability in Huntington disease.
    Veitch NJ; Ennis M; McAbney JP; ; Shelbourne PF; Monckton DG
    DNA Repair (Amst); 2007 Jun; 6(6):789-96. PubMed ID: 17293170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 1976C>T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo.
    Riksen NP; Franke B; van den Broek P; Smits P; Rongen GA
    Pharmacogenet Genomics; 2007 Jul; 17(7):551-4. PubMed ID: 17558310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CAG repeat length on psychiatric disorders in Huntington's disease.
    Vassos E; Panas M; Kladi A; Vassilopoulos D
    J Psychiatr Res; 2008 Jun; 42(7):544-9. PubMed ID: 17610899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association study of A2a adenosine receptor genetic polymorphism in panic disorder.
    Lam P; Hong CJ; Tsai SJ
    Neurosci Lett; 2005 Apr; 378(2):98-101. PubMed ID: 15774265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma.
    Kim SH; Kim YK; Park HW; Kim SH; Kim SH; Ye YM; Min KU; Park HS
    Respir Med; 2009 Mar; 103(3):356-63. PubMed ID: 19019667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's disease-like 2 in Brazil--report of 4 patients.
    Rodrigues GG; Walker RH; Brice A; Cazeneuve C; Russaouen O; Teive HA; Munhoz RP; Becker N; Raskin S; Werneck LC; Junior WM; Tumas V
    Mov Disord; 2008 Nov; 23(15):2244-7. PubMed ID: 18816802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association study of adenosine A2a receptor (1976C>T) genetic polymorphism and mood disorders and age of onset.
    Tsai SJ; Hong CJ; Hou SJ; Yen FC
    Psychiatr Genet; 2006 Oct; 16(5):185. PubMed ID: 16969271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease.
    Maglione V; Giallonardo P; Cannella M; Martino T; Frati L; Squitieri F
    Am J Med Genet B Neuropsychiatr Genet; 2005 Nov; 139B(1):101-5. PubMed ID: 16184606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.